Background illustration for clinical trials search

Paid Clinical Trials Billings

Discover 125 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 125

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Billings MT, Great Falls MT, Cheyenne WY,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Billings MT, Bozeman MT, Great Falls MT, Missoula MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase2, Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for

Prostate Cancer (Adenocarcinoma)

Location: Billings MT, Cody WY, Bozeman MT, Great Falls MT,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06592924

Phase3, Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for

Recurrent Non-Muscle Invasive Bladder Carcinoma,

Location: Billings MT, Cody WY, Bozeman MT, Great Falls MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07000084

Phase3, Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements,

Location: Billings MT, Missoula MT, Coeur d'Alene ID,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06649812

Phase2, Recruiting

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for

Head and Neck Squamous Cell Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06992427

Phase3, Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for

Castration-Resistant Prostate Carcinoma,

Location: Billings MT, Fort Collins CO, Loveland CO, Greeley CO,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06632977

Phase2, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase2, Recruiting

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

for

Prostate Cancer

Location: Billings MT, Roseville CA, Sacramento CA, Stockton CA,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06235697

Phase3, Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for

Biochemically Recurrent Prostate Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Havre MT,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male

Age: 18+

Code: NCT04423211

Phase3, Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554393

Phase2, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT06031688

Phase2, Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

for

Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8,

Location: Billings MT, Cody WY, Sheridan WY, Bozeman MT,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT05806515

Phase2, Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04269902

Phase3, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

Paid Clinical Trials Billings

Filter results

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Interested in new trials?

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)